Given our findings and the extensive HCC specimen analysis, we propose that a combinatorial approach involving systematic anti-checkpoint therapy (targeting CCR4 and CD73) and TACE might offer a promising avenue for post-operative HCC management. Here, CCR4 is linked to hepatocellular carcinoma.